Omar I. Vivar

656 total citations
19 papers, 514 citations indexed

About

Omar I. Vivar is a scholar working on Oncology, Genetics and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Omar I. Vivar has authored 19 papers receiving a total of 514 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 7 papers in Genetics and 6 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Omar I. Vivar's work include Estrogen and related hormone effects (6 papers), Radiopharmaceutical Chemistry and Applications (4 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Omar I. Vivar is often cited by papers focused on Estrogen and related hormone effects (6 papers), Radiopharmaceutical Chemistry and Applications (4 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Omar I. Vivar collaborates with scholars based in United States, France and Australia. Omar I. Vivar's co-authors include Elise F. Saunier, Dale C. Leitman, Terence P. Speed, Isaac Cohen, Mary Tagliaferri, Leonard F. Bjeldanes, Gary L. Firestone, Sebastián Amigorena, Chia-Lei Lin and Jean-Marie Carpier and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Omar I. Vivar

18 papers receiving 502 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Omar I. Vivar United States	9	218	170	164	85	44	19	514
Stéphane Courtois Belgium	11	320 1.5×	114 0.7×	103 0.6×	50 0.6×	92 2.1×	14	564
Masashi Yamasaki Japan	12	140 0.6×	67 0.4×	136 0.8×	48 0.6×	68 1.5×	17	458
Jun‐Ho Cho United States	18	385 1.8×	168 1.0×	126 0.8×	37 0.4×	21 0.5×	32	747
Sadeq Vallian Iran	15	651 3.0×	151 0.9×	133 0.8×	124 1.5×	24 0.5×	66	905
Teng Ji China	16	347 1.6×	87 0.5×	86 0.5×	190 2.2×	34 0.8×	29	642
Linah Al-Alem United States	14	259 1.2×	61 0.4×	166 1.0×	109 1.3×	18 0.4×	25	602
Vivek Reddy Palicharla United States	9	508 2.3×	152 0.9×	48 0.3×	115 1.4×	33 0.8×	13	649
Amanda K. Ashley United States	13	461 2.1×	95 0.6×	53 0.3×	218 2.6×	41 0.9×	24	688
Gabriel L. Fiszman Argentina	14	258 1.2×	88 0.5×	65 0.4×	195 2.3×	62 1.4×	26	512
Samisubbu R. Naidu United States	13	405 1.9×	69 0.4×	58 0.4×	88 1.0×	13 0.3×	18	594

Countries citing papers authored by Omar I. Vivar

Since Specialization

Citations

This map shows the geographic impact of Omar I. Vivar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Omar I. Vivar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Omar I. Vivar more than expected).

Fields of papers citing papers by Omar I. Vivar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Omar I. Vivar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Omar I. Vivar. The network helps show where Omar I. Vivar may publish in the future.

Co-authorship network of co-authors of Omar I. Vivar

This figure shows the co-authorship network connecting the top 25 collaborators of Omar I. Vivar. A scholar is included among the top collaborators of Omar I. Vivar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Omar I. Vivar. Omar I. Vivar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Tourneau, Christophe Le, Zoltán Takácsi‐Nagy, Sandra Nuyts, et al.. (2025). Nanoray-312: phase III study of NBTXR3 + radiotherapy ± cetuximab in elderly, platinum-ineligible locally advanced HNSCC. Future Oncology. 21(12). 1489–1499. 3 indexed citations

Chajon, É., Marc Pracht, Yan Rolland, et al.. (2025). Radioenhancing Hafnium Oxide Nanoparticles (NBTXR3) Followed by Stereotactic Body Radiation Therapy in Patients With Hepatocellular Carcinoma and Liver Metastases (NBTXR3-103): Phase 1 Dose-Escalation Trial. Advances in Radiation Oncology. 11(1). 101937–101937.

Shen, Colette J., Jessica M. Frakes, Trevor Hackman, et al.. (2024). Early signs of efficacy in patients with anti-PD-1 naïve and anti-PD-1 resistant HNSCC treated with NBTXR3/SBRT in combination with nivolumab or pembrolizumab in the phase I trial Study 1100.. Journal of Clinical Oncology. 42(16_suppl). 6035–6035. 3 indexed citations

Liem, X., Thierry de Baère, Omar I. Vivar, et al.. (2024). International guidelines for intratumoral and intranodal injection of NBTXR3 nanoparticles in head and neck cancers. Head & Neck. 46(6). 1253–1262. 10 indexed citations

Tourneau, C. Le, X. Liem, Sophie El Bedoui, et al.. (2024). Novel Radioenhancer NBTXR3 Activated by Radiotherapy in Cisplatin-Ineligible Locally Advanced HNSCC Patients: Final and Exploratory Results of a Phase I Trial. International Journal of Radiation Oncology*Biology*Physics. 118(5). e6–e6. 3 indexed citations

Katz, Matthew H. G., Naruhiko Ikoma, Michael J. Overman, et al.. (2023). 1631P Phase I study of endoscopic ultrasound (EUS)-guided NBTXR3 delivery activated by radiotherapy (RT) for locally advanced or borderline resectable pancreatic cancer (LAPC or BRPC). Annals of Oncology. 34. S903–S903. 2 indexed citations

Tourneau, Christophe Le, Zoltán Takácsi‐Nagy, X. Liem, et al.. (2023). 887P Antitumor activity of the radioenhancer NBTXR3 on injected lesions to estimate overall survival: Exploratory analyses from a phase I in cisplatin-ineligible locally advanced HNSCC patients. Annals of Oncology. 34. S568–S569. 3 indexed citations

Shen, Colette J., Jessica M. Frakes, Jiaxin Niu, et al.. (2023). Efficacy from the ongoing phase I trial Study 1100 with NBTXR3 activated by radiotherapy in combination with nivolumab or pembrolizumab in patients with locoregionally recurrent or metastatic HNSCC.. Journal of Clinical Oncology. 41(16_suppl). 6038–6038. 6 indexed citations

Frakes, Jessica M., Jiaxin Niu, Jared Weiss, et al.. (2022). 684 NBTXR3 activated by radiotherapy in combination with nivolumab or pembrolizumab in patients with advanced cancers: results from an ongoing dose escalation phase I trial (Study 1100). Regular and Young Investigator Award Abstracts. A714–A714. 5 indexed citations

10.

Ginat, Daniel Thomas, Aditya Juloori, Omar I. Vivar, et al.. (2022). Imaging Features of Intratumoral Injection of NBTXR3 for Head and Neck Squamous Cell Carcinoma Lymph Node Metastases. Diagnostics. 12(9). 2156–2156. 8 indexed citations

11.

Vivar, Omar I., João G. Magalhães, & Sebastián Amigorena. (2016). Measurement of Export to the Cytosol in Dendritic Cells Using a Cytofluorimetry-Based Assay. Methods in molecular biology. 1423. 183–188. 4 indexed citations

12.

Alloatti, Andrés, Fiorella Kotsias, Jean-Marie Carpier, et al.. (2015). Toll-like Receptor 4 Engagement on Dendritic Cells Restrains Phago-Lysosome Fusion and Promotes Cross-Presentation of Antigens. Immunity. 43(6). 1087–1100. 148 indexed citations

13.

Vivar, Omar I., Jean-Marie Carpier, João G. Magalhães, et al.. (2015). IFT20 controls LAT recruitment to the immune synapse and T-cell activation in vivo. Proceedings of the National Academy of Sciences. 113(2). 386–391. 45 indexed citations

14.

Saunier, Elise F., Omar I. Vivar, Xiaoyue Zhao, et al.. (2011). Estrogenic Plant Extracts Reverse Weight Gain and Fat Accumulation without Causing Mammary Gland or Uterine Proliferation. PLoS ONE. 6(12). e28333–e28333. 10 indexed citations

15.

Vivar, Omar I., Elise F. Saunier, Dale C. Leitman, Gary L. Firestone, & Leonard F. Bjeldanes. (2010). Selective Activation of Estrogen Receptor-β Target Genes by 3,3′-Diindolylmethane. Endocrinology. 151(4). 1662–1667. 29 indexed citations

16.

Leitman, Dale C., Sreenivasan Paruthiyil, Omar I. Vivar, et al.. (2010). Regulation of specific target genes and biological responses by estrogen receptor subtype agonists. Current Opinion in Pharmacology. 10(6). 629–636. 70 indexed citations

17.

Vivar, Omar I., Xiaoyue Zhao, Elise F. Saunier, et al.. (2010). Estrogen Receptor β Binds to and Regulates Three Distinct Classes of Target Genes. Journal of Biological Chemistry. 285(29). 22059–22066. 92 indexed citations

18.

Levy, Nitzan, Sreenivasan Paruthiyil, Xiaoyue Zhao, et al.. (2009). Unliganded estrogen receptor-β regulation of genes is inhibited by tamoxifen. Molecular and Cellular Endocrinology. 315(1-2). 201–207. 21 indexed citations

19.

Vivar, Omar I., Chia-Lei Lin, Gary L. Firestone, & Leonard F. Bjeldanes. (2009). 3,3′-Diindolylmethane induces a G1 arrest in human prostate cancer cells irrespective of androgen receptor and p53 status. Biochemical Pharmacology. 78(5). 469–476. 52 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact